BACKGROUND: Estimation of HIV incidence rates is important for timing interventions, planning prevention studies, and monitoring the epidemic. This requires accurate estimation of the "recency period" (also known as the "window period") between seroconversion and achievement of specific detectable levels of anti-HIV antibody titers, such as the standardized optical density (SOD) in the early phase of HIV-1 infection. METHODS: To obtain a better understanding of interpatient variation of the recency period, prospective measurements of antiviral antibody titers in the early phase of HIV-1 subtype C infection were quantified by Vironostika-LS. Time of seroconversion was estimated by Fiebig staging. RESULTS: The profiles of SOD values during the first year of infection commonly showed slow initial increase followed by a more rapid increase, although in some patients, SOD values increased rapidly soon after seroconversion. Using an SOD cutoff of 1.0, the average duration of the recency period in subtype C infection in the local epidemic in Botswana was estimated to be 151 days (95% confidence interval: 130 to 172 days) post seroconversion. The recency period was significantly associated (P = 0.007) with the level of viral replication during the first 2-3 months post seroconversion. Reduction of SOD values after initiation of antiretroviral therapy (ART) was a dominant pattern in antiretroviral drug (ARV)-treated subjects. CONCLUSIONS: Our data suggest that HIV incidence estimation based on sensitive/less sensitive enzyme immunoassay cross-sectional testing could be potentially improved by incorporation of viral load levels at the time of detection of a recent infection.
BACKGROUND: Estimation of HIV incidence rates is important for timing interventions, planning prevention studies, and monitoring the epidemic. This requires accurate estimation of the "recency period" (also known as the "window period") between seroconversion and achievement of specific detectable levels of anti-HIV antibody titers, such as the standardized optical density (SOD) in the early phase of HIV-1 infection. METHODS: To obtain a better understanding of interpatient variation of the recency period, prospective measurements of antiviral antibody titers in the early phase of HIV-1 subtype C infection were quantified by Vironostika-LS. Time of seroconversion was estimated by Fiebig staging. RESULTS: The profiles of SOD values during the first year of infection commonly showed slow initial increase followed by a more rapid increase, although in some patients, SOD values increased rapidly soon after seroconversion. Using an SOD cutoff of 1.0, the average duration of the recency period in subtype C infection in the local epidemic in Botswana was estimated to be 151 days (95% confidence interval: 130 to 172 days) post seroconversion. The recency period was significantly associated (P = 0.007) with the level of viral replication during the first 2-3 months post seroconversion. Reduction of SOD values after initiation of antiretroviral therapy (ART) was a dominant pattern in antiretroviral drug (ARV)-treated subjects. CONCLUSIONS: Our data suggest that HIV incidence estimation based on sensitive/less sensitive enzyme immunoassay cross-sectional testing could be potentially improved by incorporation of viral load levels at the time of detection of a recent infection.
Authors: M K Morris; D A Katzenstein; D Israelski; A Zolopa; R M Hendry; C V Hanson Journal: J Acquir Immune Defic Syndr Date: 2001-12-15 Impact factor: 3.731
Authors: Denise Kothe; Robert H Byers; Samuel P Caudill; Glen A Satten; Robert S Janssen; W Harry Hannon; Joanne V Mei Journal: J Acquir Immune Defic Syndr Date: 2003-08-15 Impact factor: 3.731
Authors: F R Cleghorn; N Jack; J R Murphy; J Edwards; B Mahabir; R Paul; T O'Brien; M Greenberg; K Weinhold; C Bartholomew; R Brookmeyer; W A Blattner Journal: Am J Epidemiol Date: 1998-05-01 Impact factor: 4.897
Authors: D J Hu; S Vanichseni; T D Mastro; S Raktham; N L Young; P A Mock; S Subbarao; B S Parekh; L Srisuwanvilai ; R Sutthent; C Wasi; W Heneine; K Choopanya Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: Bhupat D Rawal; Azucena Degula; Ludmila Lebedeva; Robert S Janssen; Frederick M Hecht; Haynes W Sheppard; Michael P Busch Journal: J Acquir Immune Defic Syndr Date: 2003-07-01 Impact factor: 3.731
Authors: Carrie L Young; Dale J Hu; Robert Byers; Suphak Vanichseni; Nancy L Young; Robert Nelson; Philip A Mock; Kachit Choopanya; Robert Janssen; Timothy D Mastro; Joanne V Mei Journal: AIDS Res Hum Retroviruses Date: 2003-06 Impact factor: 2.205
Authors: Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch Journal: JAMA Date: 1998-07-01 Impact factor: 56.272
Authors: Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u Journal: J Virol Date: 2011-02-02 Impact factor: 5.103
Authors: Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex Journal: Virology Date: 2011-10-19 Impact factor: 3.616
Authors: Wen Xie; Denis Agniel; Andrey Shevchenko; Sergey V Malov; Anton Svitin; Nikolay Cherkasov; Marianna K Baum; Adriana Campa; Simani Gaseitsiwe; Hermann Bussmann; Joseph Makhema; Richard Marlink; Vladimir Novitsky; Tun-Hou Lee; Tianxi Cai; Stephen J O'Brien; M Essex Journal: AIDS Res Hum Retroviruses Date: 2017-04-06 Impact factor: 2.205
Authors: Timothy D Mastro; Andrea A Kim; Timothy Hallett; Thomas Rehle; Alex Welte; Oliver Laeyendecker; Tom Oluoch; Jesus M Garcia-Calleja Journal: J HIV AIDS Surveill Epidemiol Date: 2010-01-01
Authors: Rui Wang; Jia Weng; Sikhulile Moyo; Debanjan Pain; Christopher D Barr; Dorcas Maruapula; Dineo Mongwato; Joseph Makhema; Vladimir Novitsky; M Essex Journal: AIDS Res Hum Retroviruses Date: 2013-04-19 Impact factor: 2.205
Authors: Vladimir Novitsky; Rui Wang; Hermann Bussmann; Shahin Lockman; Marianna Baum; Roger Shapiro; Ibou Thior; Carolyn Wester; C William Wester; Anthony Ogwu; Aida Asmelash; Rosemary Musonda; Adriana Campa; Sikhulile Moyo; Erik van Widenfelt; Madisa Mine; Claire Moffat; Mompati Mmalane; Joseph Makhema; Richard Marlink; Peter Gilbert; George R Seage; Victor DeGruttola; M Essex Journal: PLoS One Date: 2010-04-12 Impact factor: 3.240
Authors: Raabya Rossenkhan; Iain J MacLeod; Zabrina L Brumme; Craig A Magaret; Theresa K Sebunya; Rosemary Musonda; Berhanu A Gashe; Paul T Edlefsen; Vlad Novitsky; M Essex Journal: AIDS Res Hum Retroviruses Date: 2016-07-26 Impact factor: 2.205
Authors: Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Lemme Kebaabetswe; Raabya Rossenkhan; Caitlin Bonney; Michaela Herzig; David Nkwe; Sikhulile Moyo; Rosemary Musonda; Elias Woldegabriel; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex Journal: PLoS One Date: 2009-11-05 Impact factor: 3.240